Boston Scientific Corporation $BSX Shares Acquired by KBC Group NV

KBC Group NV increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 2.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,044,385 shares of the medical equipment provider’s stock after purchasing an additional 84,768 shares during the period. Boston Scientific accounts for about 0.7% of KBC Group NV’s investment portfolio, making the stock its 23rd largest holding. KBC Group NV’s holdings in Boston Scientific were worth $290,281,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Crown Wealth Group LLC boosted its stake in Boston Scientific by 4.7% during the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock valued at $218,000 after purchasing an additional 100 shares in the last quarter. Claret Asset Management Corp raised its stake in shares of Boston Scientific by 4.4% in the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after buying an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC raised its stake in shares of Boston Scientific by 5.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after buying an additional 103 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors lifted its holdings in shares of Boston Scientific by 2.3% in the third quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 4,776 shares of the medical equipment provider’s stock valued at $466,000 after buying an additional 108 shares during the period. Finally, Kera Capital Partners Inc. boosted its stake in Boston Scientific by 3.3% during the third quarter. Kera Capital Partners Inc. now owns 3,407 shares of the medical equipment provider’s stock valued at $333,000 after buying an additional 109 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analyst support remains: Truist trimmed its price target to $90 but kept a Buy rating, and Citi has reiterated a Buy stance (prior target reductions noted). The sustained Buy ratings support upside sentiment despite lower targets. Truist price target note Citi reiteration
• Positive Sentiment: Earnings expectations are constructive: recent pieces (Zacks, Yahoo) highlight that BSX appears positioned for an earnings beat in the upcoming report, citing favorable revenue/expense dynamics and consensus-beating potential—this can support near-term upside if results meet or beat expectations. Zacks earnings preview Yahoo earnings preview
• Neutral Sentiment: Competitive landscape update: AIP’s announced $1.27B take-private of Avanos (a competitor in some product areas) could change competitive dynamics in adjacent markets, but direct impact on BSX revenue/margins is unclear at this stage. MedTechDive Avanos takeover
• Neutral Sentiment: Market commentary: Overnight/early coverage noted BSX outperformed the broader market in recent sessions, reflecting mixed investor responses to the above factors. Zacks market note
• Negative Sentiment: Legal risk rising: Multiple law firms have filed or announced investor alerts about securities-class-action claims alleging that BSX (and some officers) misrepresented U.S. electrophysiology procedure growth; several firms are soliciting lead-plaintiff motions with a May 4, 2026 deadline. This cluster of lawsuits increases litigation risk and could pressure the stock if damages or disclosures follow. Rosen class action notice Levi & Korsinsky alert

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Stock Up 1.2%

Shares of Boston Scientific stock opened at $64.61 on Thursday. The stock’s fifty day moving average is $70.12 and its 200-day moving average is $87.35. The firm has a market capitalization of $96.02 billion, a PE ratio of 33.30, a price-to-earnings-growth ratio of 0.99 and a beta of 0.78. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 12-month low of $60.59 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter last year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of research analyst reports. Argus raised Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Canaccord Genuity Group cut their price target on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Royal Bank Of Canada restated an “outperform” rating and set a $115.00 price objective on shares of Boston Scientific in a research report on Monday, March 30th. Wells Fargo & Company lowered their price objective on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Finally, Morgan Stanley dropped their target price on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $102.82.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.